Welcome to Thuris Corporation

Thuris is focused on the development of pharmaceuticals for select niche indications, including: a stroke-related condition, peripheral neuropathy, and Huntington's disease. The Company also has received FDA clearance for a 510(k) medical device, the NeuroGraphTM, designed to aide in diagnosis, clinical trial enrollment, and endpoint monitoring for Central Nervous System (CNS) disorders.

Pharmaceuticals

Thuris' drug development efforts originated from the Company's in vitro and in vivo animal models that recreate the hallmarks (including brain inflammation, neuronal inclusions, neurofibrillary tangles, amyloid toxicity, etc.) of major neurodegenerative diseases in just days -- a significant leap forward for neuroprotective drug development. Such advances have enabled Thuris to focus on developing mechanism-based compounds to treat select disorders. Thuris intends, through its co-development partnerships, as well as with its own in-house drug leads, to forward multiple anti-neurodegenerative therapeutics to the clinic. To this end, Thuris has partnered with Cephalon (USA; www.cephalon.com), Sigma-Tau Pharmaceuticals (Italy; www.sigma-tau.it), D-Pharm (Israel; www.dpharm.com), Degussa (Germany; www.degussa.com), PRAECIS Pharmaceuticals (USA; www.praecis.com), the Chinese National Center for Drug Screening (Shanghai), and SiniWest China.

Non-Invasive Medical Device

Thuris has received 510k FDA clearance for a non-invasive medical device that assists in the diagnosis of psychiatric and neurological disorders over a broad range of brain-related conditions. The device, the NeuroGraph, is based upon Electroencephalography (EEG) and Event Related Potentials (ERP) and includes proprietary statistical learning methods. The software advances allow the device to function as a powerful clinical development tool and psychiatric diagnostic aid. The NeuroGraph provides an objective and time sensitive measure of cognitive and psychiatric functioning. Thuris intends to market the NeuroGraph to pharmaceutical companies for enrollment and endpoint monitoring in CNS clinical trials. Future development includes a version of the product for psychiatrists, neurologists, and other physicians involved in CNS diagnosis and treatments.